Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEACON study of NKTR-102 versus physician's choice chemotherapy in previously treated metastatic breast cancer
NL-OMON41606Phase 3Not yet recruiting
- Sponsor
- Nektar Therapeutics
- Start
- Jul 2012
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of etirinotecan pegol in breast cancer (2 arms), sponsored by Nektar Therapeutics. Primary endpoint: Overall survival. Planned start Jul 2012; status: not yet recruiting.
02
Drugs
etirinotecan pegol
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON41606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41606.